Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Related Citations for PubMed (Select 23738582)

1.

Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.

Markert C, Schweizer Y, Hellwig R, Wirsching T, Riedel KD, Burhenne J, Weiss J, Mikus G, Haefeli WE.

Br J Clin Pharmacol. 2014 Jan;77(1):141-8. doi: 10.1111/bcp.12177.

2.

Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1.

Markert C, Hellwig R, Burhenne J, Hoffmann MM, Weiss J, Mikus G, Haefeli WE.

Eur J Clin Pharmacol. 2013 Oct;69(10):1785-93. doi: 10.1007/s00228-013-1529-1. Epub 2013 Jun 9.

PMID:
23748747
3.

Influence of St. John's wort on the steady-state pharmacokinetics and metabolism of bosentan.

Markert C, Ngui P, Hellwig R, Wirsching T, Kastner IM, Riedel KD, Burhenne J, Weiss J, Mikus G, Haefeli WE.

Int J Clin Pharmacol Ther. 2014 Apr;52(4):328-36. doi: 10.5414/CP202048.

PMID:
24472406
4.

Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.

Werner D, Werner U, Meybaum A, Schmidt B, Umbreen S, Grosch A, Lestin HG, Graf B, Zolk O, Fromm MF.

Clin Pharmacokinet. 2008;47(5):323-32.

PMID:
18399713
5.

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD.

Clin Pharmacol Ther. 1998 Aug;64(2):133-43.

PMID:
9728893
6.

Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects.

van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J.

Clin Pharmacol Ther. 2007 Mar;81(3):414-9. Epub 2007 Jan 24. Erratum in: Clin Pharmacol Ther. 2007 Mar;81(3):460.

PMID:
17251982
7.
8.

Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers.

Liukas A, Hagelberg NM, Kuusniemi K, Neuvonen PJ, Olkkola KT.

J Clin Psychopharmacol. 2011 Jun;31(3):302-8. doi: 10.1097/JCP.0b013e3182189892.

PMID:
21508859
9.

Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.

Quinney SK, Zhang X, Lucksiri A, Gorski JC, Li L, Hall SD.

Drug Metab Dispos. 2010 Feb;38(2):241-8. doi: 10.1124/dmd.109.028746. Epub 2009 Nov 2.

10.

A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.

Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE.

Clin Pharmacol Ther. 2013 Jun;93(6):564-71. doi: 10.1038/clpt.2013.27. Epub 2013 Feb 8.

PMID:
23511711
11.

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.

Dingemanse J, van Giersbergen PL.

Clin Pharmacokinet. 2004;43(15):1089-115. Review.

PMID:
15568889
12.

Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.

Shin J, Pauly DF, Pacanowski MA, Langaee T, Frye RF, Johnson JA.

Pharmacotherapy. 2011 Oct;31(10):942-50. doi: 10.1592/phco.31.10.942.

13.

Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.

Pinto AG, Wang YH, Chalasani N, Skaar T, Kolwankar D, Gorski JC, Liangpunsakul S, Hamman MA, Arefayene M, Hall SD.

Clin Pharmacol Ther. 2005 Mar;77(3):178-88.

PMID:
15735612
14.

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.

Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivistö KT, Neuvonen PJ.

Clin Pharmacol Ther. 2005 Jun;77(6):468-78.

PMID:
15961978
15.

Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.

Quinney SK, Malireddy SR, Vuppalanchi R, Hamman MA, Chalasani N, Gorski JC, Hall SD.

Eur J Clin Pharmacol. 2013 Mar;69(3):439-48. doi: 10.1007/s00228-012-1339-x. Epub 2012 Jul 10.

16.

Interaction between midazolam and clarithromycin in the elderly.

Quinney SK, Haehner BD, Rhoades MB, Lin Z, Gorski JC, Hall SD.

Br J Clin Pharmacol. 2008 Jan;65(1):98-109. Epub 2007 Jul 17.

17.

Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.

Gupta P, Alvey C, Wang R, Dowty ME, Fahmi OA, Walsky RL, Riese RJ, Krishnaswami S.

Br J Clin Pharmacol. 2012 Jul;74(1):109-15. doi: 10.1111/j.1365-2125.2012.04168.x.

18.

Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.

Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, Cheboyina S.

J Clin Pharmacol. 2006 Feb;46(2):201-13.

19.

Cyclosporine markedly raises the plasma concentrations of repaglinide.

Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT.

Clin Pharmacol Ther. 2005 Oct;78(4):388-99.

PMID:
16198658
20.

Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.

van Giersbergen PL, Halabi A, Dingemanse J.

Br J Clin Pharmacol. 2002 Jun;53(6):589-95.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk